secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0000950170-23-004638
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines reports FY2022 net loss $248.7M; cash $644.9M; provides clinical updates
--------------------------------------------------------------------------------

- Net loss $248.7M for FY2022 vs $187.1M in 2021; Q4 net loss $56.5M.
- Cash, equivalents and securities $644.9M as of Dec 31, 2022; expects to fund operations through 2024.
- Revenue $35.4M in FY2022 includes $7.6M non-cash adjustment from Sanofi collaboration termination.
- RMC-6236 shows early antitumor activity: 12 evaluable patients all stable or better, 10 with tumor reductions, 2 partial responses.
- Sanofi terminates SHP2 collaboration effective June 2023; Revolution regains global rights to RMC-4630.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000095017023004638/0000950170-23-004638-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000095017023004638/rvmd-20230227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-004638

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer